Development of an Optimized Adjuvanted TB Vaccine

NIH RePORTER · NIH · N01 · $2,076,197 · view on reporter.nih.gov ↗

Abstract

Vaccine Adjuvant Discovery Program: To develop a lead, optimized adjuvanted tuberculosis (TB) vaccine for IM or IN administration using specified adjuvants in combination with recombinant or circRNA TB antigens within the context of a vaccine to prevent TB.

Key facts

NIH application ID: 10681631
Project number: 75N93019C00045-P00012-9999-3
Recipient: UNIVERSITY OF MONTANA
Principal Investigator: JAY EVANS
Activity code: N01
Funding institute: NIH
Fiscal year: 2022
Award amount: $2,076,197
Award type: —
Project period: 2021-09-30 → 2022-09-29